News
Baxter Announces Appointment of Interim President for Its Renal Business
Baxter International Inc. announced that Jill Schaaf, who served as President, Renal, since May 2014, will be leaving the company. Effective May 3, 2016, Giuseppe Accogli, former region head for Baxter’s U.S. Renal business, has assumed the role of...
News
Alexion to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Alexion Pharmaceuticals, Inc announced that management will present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas on Tuesday, May 10, 2016 at 10:40 a.m., Pacific Time. An audio webcast of...
News
AbbVie to Acquisition of Stemcentrx and its Novel
AbbVie a global biopharmaceutical company, announced that it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer (SCLC). Rova-T is a novel biomarker-specific therapy that is derived...
News
Eli Lilly To Participate In Bank Of America Merrill Lynch 2016 Health Care Conference
Eli Lilly and Company will attend the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016. David Ricks, Lilly senior vice president and president of Lilly Bio-Medicines, will participate in a fireside chat at 8:00...
News
Mallinckrodt to Present at UBS Global Healthcare Conference
Mallinckrodt Pharmaceuticals a leading global specialty biopharmaceutical company, will present on Tuesday, May 24, 2016, at the UBS Global Healthcare Conference at the Grand Hyatt New York, 109 E. 42nd St., New York. World pharma today/News/-Matthew...
News
AstraZeneca enters into US licensing agreement with Ironwood Pharmaceuticals for lesinurad
AstraZeneca announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA) in December 2015, in combination with a...
News
Ironwood, AstraZeneca enter U.S. licensing agreement for lesinurad
AstraZeneca announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA) in December 2015, in combination with a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















